The US Food and Drug Administration (FDA) has approval for  and 鈥檚 Enhertu (fam-trastuzumab deruxtecan-nxki) to treat unresectable or metastatic non-small cell lung cancer (NSCLC) in adults.

The treatment is indicated for such patients whose tumours have activating HER2 (ERBB2) mutations and previously received systemic therapy.听

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile 鈥� free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Based on objective response rate (ORR) and duration of response (DoR), the indication received approval under an accelerated pathway.

The latest approval was based on the findings from the Phase II DESTINY-Lung02 clinical trial, which assessed the safety and efficacy of two doses of Enhertu in HER2 mutant metastatic NSCLC patients.听

According to the interim efficacy data from a pre-specified patient cohort, a 5.4 mg/kg dose of Enhertu was found to provide a confirmed ORR of 57.7%, as evaluated by blinded independent central review (BICR). 

In the trial, 1.9% and 55.8% of subjects had complete and partial responses, respectively, with a median duration of response of 8.7 months.

A specifically engineered HER2-directed antibody drug conjugate (ADC), Enhertu is being co-developed and co-marketed by along with .

Enhertu is claimed to be the first HER2-directed therapy to receive approval for treating HER2 mutant metastatic NSCLC patients. 

Subsequent to US approval for the new indication, Daiichi Sankyo is entitled to receive a milestone payment of $125m from AstraZeneca.

Daiichi Sankyo president and CEO and Oncology Business global head Ken Keller said: 鈥淲e are excited that the FDA has granted accelerated approval for Enhertu for patients with HER2 mutant metastatic non-small cell lung cancer. 

鈥淓nhertu has now been approved in three different tumour types, underscoring its significant potential across several HER2 targetable tumours. 

鈥淲e are continuing to evaluate the efficacy and safety of Enhertu versus standard chemotherapy in our DESTINY clinical trials in lung cancer.鈥�

The latest development comes after Enhertu received FDA approval for treating unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer.